175 related articles for article (PubMed ID: 10930803)
1. Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer.
Huiping C; Jonasson JG; Agnarsson BA; Sigbjornsdottir BI; Huebner K; Ingvarsson S
Eur J Cancer; 2000 Aug; 36(12):1552-7. PubMed ID: 10930803
[TBL] [Abstract][Full Text] [Related]
2. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas.
Ingvarsson S; Agnarsson BA; Sigbjornsdottir BI; Kononen J; Kallioniemi OP; Barkardottir RB; Kovatich AJ; Schwarting R; Hauck WW; Huebner K; McCue PA
Cancer Res; 1999 Jun; 59(11):2682-9. PubMed ID: 10363992
[TBL] [Abstract][Full Text] [Related]
3. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
Ismail HM; Medhat AM; Karim AM; Zakhary NI
Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity in bilateral breast cancer.
Kollias J; Man S; Marafie M; Carpenter K; Pinder S; Ellis IO; Blamey RW; Cross G; Brook JD
Breast Cancer Res Treat; 2000 Dec; 64(3):241-51. PubMed ID: 11200774
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.
Beckmann MW; Picard F; An HX; van Roeyen CR; Dominik SI; Mosny DS; Schnürch HG; Bender HG; Niederacher D
Br J Cancer; 1996 May; 73(10):1220-6. PubMed ID: 8630282
[TBL] [Abstract][Full Text] [Related]
7. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity in the fragile histidine triad (FHIT) locus and expression analysis of FHIT protein in patients with breast disorders.
Rabelo RA; Antunes LM; Etchebehere RM; Nomelini RS; Nascentes GA; Murta EF; Pedrosa AL
Clin Exp Obstet Gynecol; 2013; 40(1):89-94. PubMed ID: 23724516
[TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma.
Xiao YP; Wu DY; Xu L; Xin Y
World J Gastroenterol; 2006 Jun; 12(23):3766-9. PubMed ID: 16773697
[TBL] [Abstract][Full Text] [Related]
10. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
Gatalica Z; Lele SM; Rampy BA; Norris BA
Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
[TBL] [Abstract][Full Text] [Related]
11. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
[TBL] [Abstract][Full Text] [Related]
12. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
13. Reduced Fhit protein expression in human malignant mesothelioma.
Pylkkänen L; Wolff H; Stjernvall T; Knuuttila A; Anttila S; Husgafvel-Pursiainen K
Virchows Arch; 2004 Jan; 444(1):43-8. PubMed ID: 14569398
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients.
Petursdottir TE; Hafsteinsdottir SH; Jonasson JG; Moller PH; Thorsteinsdottir U; Huiping C; Egilsson V; Ingvarsson S
Anticancer Res; 2002; 22(6A):3205-12. PubMed ID: 12530066
[TBL] [Abstract][Full Text] [Related]
15. [Association of fragile histidine triad gene (FHIT) with susceptibility to esophageal cancer. A preliminary study].
Li W; Wang X; Cheng G
Zhonghua Zhong Liu Za Zhi; 1998 Jul; 20(4):258-60. PubMed ID: 10920977
[TBL] [Abstract][Full Text] [Related]
16. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma.
Wistuba II; Ashfaq R; Maitra A; Alvarez H; Riquelme E; Gazdar AF
Am J Pathol; 2002 Jun; 160(6):2073-9. PubMed ID: 12057912
[TBL] [Abstract][Full Text] [Related]
17. Alteration of the fragile histidine triad gene in intrahepatic cholangiocarcinoma.
Koch E; Fiedler W; Tannapfel A; Ballhausen WG
Eur J Gastroenterol Hepatol; 2003 Aug; 15(8):907-13. PubMed ID: 12867802
[TBL] [Abstract][Full Text] [Related]
18. Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil.
Santos SC; Cavalli LR; Cavalli IJ; Lima RS; Haddad BR; Ribeiro EM
J Clin Pathol; 2004 Apr; 57(4):374-7. PubMed ID: 15047740
[TBL] [Abstract][Full Text] [Related]
19. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
Singh RB; Amare Kadam PS
Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
[TBL] [Abstract][Full Text] [Related]
20. [Loss of fragile histidine triad expression and metastasis in breast cancer].
Zhao P; Li XY; Chen LZ
Ai Zheng; 2002 Jun; 21(6):668-70. PubMed ID: 12452072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
